Equities Analysts Issue Forecasts for Humacyte Q2 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Humacyte in a report released on Thursday, June 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.09) per share for the quarter, up from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Humacyte’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at $0.00 EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $0.50 EPS.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.

Several other analysts also recently commented on HUMA. BTIG Research reissued a “buy” rating and issued a $2.00 target price on shares of Humacyte in a research report on Monday, June 8th. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. Benchmark increased their target price on shares of Humacyte to $2.00 and gave the stock a “speculative buy” rating in a research report on Monday, June 1st. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.57.

Humacyte Price Performance

Shares of HUMA opened at $1.06 on Monday. The firm has a market cap of $234.23 million, a PE ratio of -1.85 and a beta of 2.45. The firm’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.03. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.84.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently made changes to their positions in the business. R Squared Ltd acquired a new position in shares of Humacyte during the 4th quarter worth about $25,000. Atom Investors LP acquired a new stake in Humacyte in the 4th quarter valued at approximately $25,000. Truist Financial Corp acquired a new stake in Humacyte in the 3rd quarter valued at approximately $28,000. Prudential Financial Inc. bought a new position in Humacyte in the 2nd quarter worth approximately $28,000. Finally, Financial Advisors Network Inc. bought a new position in Humacyte in the 2nd quarter worth approximately $28,000. 44.71% of the stock is currently owned by institutional investors.

Insider Transactions at Humacyte

In related news, CFO Dale A. Sander sold 45,887 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the sale, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. This represents a 14.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares in the company, valued at $245,441.70. The trade was a 14.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is owned by corporate insiders.

Trending Headlines about Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: HC Wainwright raised its longer-term earnings estimates for Humacyte, including FY2028 to breakeven, FY2029 to $0.20 EPS, and FY2030 to $0.50 EPS, suggesting improving profitability over time.
• Positive Sentiment: The analyst also modestly improved several near- and medium-term EPS estimates, including Q2 2026, Q3 2026, Q4 2026, Q2 2027, Q3 2027, Q4 2027, FY2026, and FY2027, which may support the stock over the longer term.
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $4.00 price target, indicating continued optimism despite the company’s ongoing losses. Humacyte stock quote
• Negative Sentiment: Even after the revisions, Humacyte is still expected to post losses in 2026 and 2027, which may weigh on investor sentiment in the near term.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.